CAMP4 Therapeutics (CAMP)
Antisense RNA medicines designed to restore protein expression in genetic diseases.
Canadian GoldCamps Completes Acquisition of Initial 85% Interest in Stealthwall West Gold Project in Northeastern Québec
Vancouver, British Columbia – TheNewswire - August 31, 2026 — Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) (“ Canadian GoldCamps ” or the “ Company ”) announces that, further to its news release dated August 18, 2026, it has completed the acquisition of an initial 85% undivided interest in the Stealthwall West Project (the “Project”), located in the Caniapiscau district of northeastern Québec. The acquisition was completed pursuant to the definitive property acquisition and option agreement dated August 17, 2026 (the “Agreement”) with the arm's length vendors of the Project (the “Vendors”). Pursuant to the Agreement, the Company acquired an initial 85% undivided interest in the Stealthwall West Project (the “Project”), located in the Caniapiscau district of northeastern Québec (the “Transaction”). The Project comprises 50 contiguous mining claims, CDC 2865583 through CDC 2865632, on NTS map sheet 23C10 in the unorganized territory of Rivière-Mouchalagane, MRC de Caniapiscau, Côte-Nord, Québec. The claims cover an aggregate area of approximately 2,612.5 hectares.
Canadian GoldCamps Enters into Agreement to Acquire Stealthwall West Gold Project in Northeastern Québec
Vancouver, British Columbia – TheNewswire - August 18, 2026 — Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) is pleased to announce that it has entered into a definitive property acquisition and option agreement dated August 17, 2026, with the arm's length vendors of the Stealthwall West Project. Pursuant to the Agreement, the Company proposes to acquire an initial 85% undivided interest in the Stealthwall West Project, located in the Caniapiscau district of northeastern Québec. The Project comprises 50 contiguous mining claims, CDC 2865583 through CDC 2865632, on NTS map sheet 23C10 in the unorganized territory of Rivière-Mouchalagane, MRC de Caniapiscau, Côte-Nord, Québec. The claims cover an aggregate area of approximately 2,612.5 hectares.
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.62 per share a year ago.
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year.
CAMP4 advances rare disease treatment for SYNGAP1 into human trials
CAMP4 Therapeutics received regulatory clearance in Australia and Argentina to begin a Phase 1/2 trial of CMP-002, its experimental ASO therapy for SYNGAP1-related disorders. The trial will enroll at least 30 children ages 2 to 18 and use a double-blind, placebo-controlled design, with placebo recipients able to transition to the treatment if early results are positive.
SIX FLAGS GREAT AMERICA ANNOUNCES CAMP TIMBER TRAIL, AN ALL-NEW FAMILY ADVENTURE FOR 2027
New woodsy-themed family area will feature nine attractions, including the Midwest's longest, tallest and fastest suspended family coaster as part of a multi-year transformation MEDIA KIT: Photo, Video & Logos GURNEE, Ill., Aug. 6, 2026 /PRNewswire/ -- Six Flags Great America, the premier theme park destination in the Chicagoland area, today announced plans to debut Camp Timber Trail, an all-new family adventure opening in 2027.
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treatment of SYNGAP1-related disorder Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treatment of SYNGAP1-related disorder
Canadian GoldCamps Completes Independent NI 43-101 Technical Report for the Mercator Gold Project
Achieving Key Regulatory Milestone and Positioning the Company for its Next Phase of Growth Vancouver, British Columbia – TheNewswire - July 28, 2026 — Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) is pleased to announce the completion of the independent National Instrument 43-101, Standards of Disclosure for Mineral Projects Technical Report, for its flagship Mercator gold and critical minerals project in the Caniapiscau District of northeastern Québec.
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder Regulatory milestone enables Company to raise up to $50 million through second closing of private placement announced September 2025 CAMBRIDGE, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that it has received clearance from Australia's Therapeutic Goods Administration (TGA) and local Human Research Ethics Committee (HREC) to initiate the Company's Phase 1/2 clinical trial of CMP-002, a potential first-in-class disease-modifying therapeutic for SYNGAP1-related disorder.
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , July 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on July 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the "Inducement Grant").
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on July 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 39,000 shares of the Company's common stock to three newly hired employees of the Company, each as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the "Inducement Grants").
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 39,000 shares of the Company's common stock to three newly hired employees of the Company, each as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).
Discovr Radio to Embed Across All Four Days of CAMP Toronto in First Major Activation with Beatcave
Live demo listening session to approve artists onto the platform in real time New “golden ticket” subscriptions reward breakout performers on the spot Studio takeover and on-site activations give creators direct access to Discovr Radio's AI powered artist promotion tools BOULDER, Colo., June 16, 2026 (GLOBE NEWSWIRE) -- Auddia Inc. (NASDAQ: AUUD) (“Auddia” or the “Company”), an AI first technology company that has built a proprietary AI platform for audio identification and classification to reinvent how consumers engage with audio and how artists get discovered, today announced that its Discovr Radio AI powered artist promotion platform will integrate across all four days of CAMP Toronto, the flagship songwriting camp and music conference hosted by partner Beatcave, taking place July 16-19, 2026.
New Analysis Strengthens Mercator Gold System and Confirms High-Grade BIF Continuity
Canadian GoldCamps says Mercator resampling returned gold in 82% of samples, confirming mineralization continuity and new high-grade targets for 2026 work.
Mercator Gold Exploration Priorities & Strategy
Company to advance NI 43-101 Technical Report; 2026 exploration campaign to follow up on promising historic work including high-grade intercepts of 5.6 metres of 4.87 g/t gold Vancouver, British Columbia, TheNewswire, May 26, 2026, Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) is pleased to provide an update on its 2026 exploration strategy for the Mercator and Courcy gold projects located in the Caniapiscau district of northeastern Québec.
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on May 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 5,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.62 per share a year ago.
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGAP1 patients in 2H 2026